Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE® From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals has acquired exclusive U.S. rights to PKU GOLIKE from Relief Therapeutics. The transaction is expected to be accretive to Eton's earnings in 2024, with PKU GOLIKE estimated to reach peak sales of over $10 million annually in a U.S. PKU medical formula market worth approximately $100 million annually.
March 22, 2024 | 6:29 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Relief Therapeutics has divested the exclusive U.S. rights to PKU GOLIKE to Eton Pharmaceuticals, a move that could impact its financials and strategic focus.
While the sale of PKU GOLIKE's U.S. rights to Eton Pharmaceuticals removes a product from Relief Therapeutics' portfolio, the financial and strategic impacts are less clear without details on the terms of the transaction and Relief's future plans.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Eton Pharmaceuticals' acquisition of PKU GOLIKE is expected to positively impact its earnings by 2024, with potential annual sales exceeding $10 million in a $100 million market.
The acquisition of PKU GOLIKE aligns with Eton Pharmaceuticals' metabolic franchise, expected to enhance its product portfolio and contribute to earnings growth by 2024. The estimated peak sales and the size of the U.S. PKU medical formula market underscore the potential financial impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90